Targeting BCL-2through Deep Learning-BasedDrug Repurposing: A Multimodal Approach Combining Diffusion-BasedGenerative Modeling, Neural Relational Inference, and In Vitro Validation

Abstract Accurate identification of repurposable BCL-2 ligands requires not only plausible bound complex structures but also a dynamic description of how ligand binding reshapes residue-level communication. Here, we present a multimodal BCL-2 repurposing workflow built with diffusion-based generative modeling for ligand-specific complex generation and an extended neural relational inference (NRI) framework for trajectory-level interaction analysis. NeuralPlexer was applied to a library of 3094 FDA-approved drugs to generate BCL-2-ligand complex conformations at scale, yielding 1294 structurally acceptable complexes for downstream prioritization. To complement static scoring, filtered candidates were evaluated by molecular docking, anticancer QSAR classification, all-atom molecular dynamics (MD) simulations, and MM/GBSA binding free-energy calculations. We then extended NRI to protein–ligand trajectories to quantify residue-ligand and residue–residue dynamic couplings, enabling comparison of candidate-specific interaction signatures against the reference BCL-2 inhibitor Venetoclax. Among the prioritized compounds, Relugolix emerged as one of the most compelling hits, combining favorable binding energetics with an NRI-derived interaction pattern closely resembling that of Venetoclax. In vitro experiments supported BCL-2 inhibition by Relugolix in a TR-FRET assay and reduced viability of LN-18 glioma cells (IC50 = 23.55 μM). Together, these results establish a strategy that couples generative complex prediction with graph-based dynamic inference for structure-guided drug repurposing and identify Relugolix as a tractable scaffold for future BCL-2 inhibitor design.